PAOG PAO GROUP INC

PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ

Sandusky, Ohio--(Newsfile Corp. - March 16, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released details on the Company's nutraceutical developments initiative following last week's introduction of adding CBD RELAX-RX to existing CBD RespRx developments. The details today are highlighted by the Company's September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis Holdings, Inc. (OTC Pink: USMJ).

PAOG is building a comprehensive CBD nutraceuticals strategy to enhance its long-term CBD pharmaceutical strategy. Management recognizes the long-term, investment and research intensive nature of developing a pharmaceutical product and has added the nutraceutical strategy to accelerate the Company's opportunity to achieve revenue starting in 2021.

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT".

PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.

PAOG is on track to introduce its first two CBD nutraceutical products in September of this year, 2021. One CBD nutraceutical product will target the COPD market and the second will target the anxiety and depression market.

In addition to PAOG's ongoing CBD nutraceutical technical developments in Puerto Rico, PAOG expects to soon announce an additional research partnership to accelerate and expand its CBD developments initiative.

PAOG is working closely with ALKM and USMJ to package and market its first two CBD nutraceutical products and anticipates a number of announcements between now and September to introduce packaging and marketing progress and prepare the market for the September product launch.

Learn more about PAOG at .

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472

To view the source version of this press release, please visit

EN
16/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PAO GROUP INC

 PRESS RELEASE

PAOG Expects Increased Visibility For Its CBD Nutraceuticals From USMJ...

PAOG Expects Increased Visibility For Its CBD Nutraceuticals From USMJ Ecommerce Campaign Sandusky, OH, Feb. 03, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to enjoy increased market visibility for its RX Branded CBD Nutraceuticals resulting from the announced earlier today. PAOG currently markets its own independent line of CBD nutraceutical products under its “RX” label available for sale on North American Cannabis Inc.’s (OTC Pink: USMJ) ecommerce site . PAOG is also working with Puration, Inc. (OTC Pink: PURA) on the develop...

 PRESS RELEASE

PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceut...

PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceuticals Development Sandusky, OH, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today republished its 2022 strategic update on the company’s CBD pharmaceutical and nutraceutical development strategy.  The update was originally released on Friday, January 27th, 2022. The update is included in its entirety below: PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks – pharmaceutical and nutraceutical. The Company is developing a cannabis extract-based therapy to tre...

 PRESS RELEASE

PAOG Publishes 2022 Strategic Update

PAOG Publishes 2022 Strategic Update Sandusky, OH, Jan. 28, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today released a 2022 strategic update on the company’s CBD pharmaceutical and nutraceutical development strategy. The update is included in its entirety below: PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks – pharmaceutical and nutraceutical. The Company is developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses including COPD.  Recent independent has confirmed PAOG’s previous conclusion...

 PRESS RELEASE

PAOG Cites Research On Hemp Compounds Effectiveness Treating Covid To ...

PAOG Cites Research On Hemp Compounds Effectiveness Treating Covid To Advance Pharmaceutical Development Sandusky, OH, Jan. 25, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today cited recently published information on research indicating CBDA and CBGA, compounds found in hemp, “block a critical step in the process the [Covid] virus uses to infect people” (). “The two compounds were identified during a chemical screening by researchers at the Linus Pauling Institute at Oregon State University. The compounds bind to spike proteins found on the virus and blocked the spike ...

 PRESS RELEASE

PAOG Confirms Farmersville Hemp Brand CBD Product Line Development For...

PAOG Confirms Farmersville Hemp Brand CBD Product Line Development For PURA Sandusky, OH, Jan. 06, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed the development of a line of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA) is underway. PURA has updated its business model over the course of the last year and is now focusing on the development of a hemp business cooperative under the brand name Farmersville Hemp.  PURA has established its new business model to build an industrial hemp business with 3 sources of revenue – education, brandi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch